X-Nico

10 unusual facts about United States Adopted Name


Aflibercept

Aflibercept (INN, USAN) is a fusion protein approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap.

Batimastat

Batimastat (INN/USAN, codenamed BB-94) is an anticancer drug that belongs to the family of drugs called angiogenesis inhibitors.

Crofelemer

Crofelemer (USAN, trade name Fulyzaq) is a drug under development for the treatment of diarrhea associated with anti-HIV drugs such as nucleoside analog reverse transcriptase inhibitors and protease inhibitors.

Generic drug

In the United States, generic drug substances are named through review and recommendation of the United States Adopted Names (USAN) Council.

Generic drugs are labeled with the name of the manufacturer and the adopted name (nonproprietary name) of the drug.

Isoprenaline

Isoprenaline (INN) or isoproterenol (USAN, trade names Medihaler-Iso and Isuprel) is a medication used for the treatment of bradycardia (slow heart rate), heart block, and rarely for asthma.

Pegdinetanib

Pegdinetanib (USAN; planned trade name Angiocept) is an investigational anti-cancer drug that acts as a selective antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2), hindering vascularization of tumors.

Tofogliflozin

Tofogliflozin (USAN, codenamed CSG452) is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi.

United States Pharmacopeia

This has a place in law via USP’s membership in the United States Adopted Names Council.

Vilanterol

Vilanterol (USAN), or triphenylacetic acid, is a long-acting beta-2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).


Cerlapirdine

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which is under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.